Coraline Dubot

Coraline Dubot

Auto-generated profile, based on publicly available information

Coraline Dubot

Institut Curie , 35 Rue Dailly, F-92210 Saint-Cloud , France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
CBClaire Bonneau
Claire Bonneau
GPGilles Paintaud
Gilles Paintaud
OTOlivier Trédan
Olivier Trédan
CDCoraline Dubot
Coraline Dubot
CDCéline Desvignes
Céline Desvignes
MGMaya Gutierrez
Maya Gutierrez

1 March 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
CDC. Dubot
C. Dubot
VBV. Bernard
V. Bernard
MSM.P. Sablin
M.P. Sablin
SVSophie VACHER
Sophie VACHER
WCW. Chemlali
W. Chemlali
IBIvan Bieche
Ivan Bieche

1 November 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
CLCharlotte Lecerf
Charlotte Lecerf
MKMaud Kamal
Maud Kamal
SVSophie VACHER
Sophie VACHER
WCWalid Chemlali
Walid Chemlali
ASAnne Schnitzler
Anne Schnitzler
Christophe Le TourneauChristophe Le Tourneau
Christophe Le Tourneau

1 August 2020 in The Breast
Verified
Journal Article
Open access
SFSophie Frank
Sophie Frank
MCMatthieu Carton
Matthieu Carton
CDCoraline Dubot
Coraline Dubot
MCMario Campone
Mario Campone
BPBarbara Pistilli
Barbara Pistilli
PCPaul Cottu
Paul Cottu
Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups ( 60 years(y)). ESME MBC database is a national cohort, collecting retrospective data from 18 participating French cancer centers between January 01, 2008 and December 31, 2014. Among 14 403 women included, 1077 (7.5%), 6436 (44.7%) and 6890 (47.8%) pts were 60 y respectively. Pts 60y) and triple negative subtypes (27.4 vs 14.6% in >60y), and more frequent visceral involvement (36.3 vs 29.8% in >60y). At a median follow-up of 48 months, median OS differed across age groups: 38.8, 38.4 and 35.6 months for pts 60y, respectively (p < 0.0001). Compared to pts <40y, older pts had a statistically significant higher risk of death (all causes of death included), although of limited clinical value (HR = 1.1, IC 95%:1.01-1.20). There was a significant trend for better OS in pts <40y with HER2+ and luminal diseases. A possible explanation is a greater use of anti-Her2 therapies as first-line treatments: 86.6, 81.9 and 74.9% for pts 60y, respectively (p < 0.0001). Although young age seems associated with more aggressive presentations at diagnosis of MBC, it has no deleterious effect on OS in this large series.

1 September 2014 in Annals of Oncology
Verified
Journal Article
Closed access
FSF. Selle
F. Selle
SWS. Wittnebel
S. Wittnebel
PBP. Biron
P. Biron
GGG. Gravis
G. Gravis
GRG. Roubaud
G. Roubaud
JLJ.P. Lotz
J.P. Lotz
High-dose chemotherapy (HDCT) is an effective salvage treatment of germ-cell tumors (GCTs) patients. In the first salvage setting, 30%-70% of patients may achieve durable remissions. Even when HDCT is administered as subsequent salvage treatment, up to 20% of patients may still be definitively cured. However, patients with refractory/relapsed disease still have a very poor long-term prognosis, requiring earlier intervention of HDCT. This phase II trial was addressed to nonrefractory patients failing Cisplatin-based chemotherapy. Inclusion criteria included seminomatous GCT in relapse after two lines of chemotherapy, nonseminomatous GCT in relapse after first or second lines, partial remission after first line, primary mediastinal GCT in first relapse. Patients received two cycles combining Epirubicin and Paclitaxel (Epi-Tax), followed by three consecutive HDCT, one using a Paclitaxel/Thiotepa (Thio-Tax) association and two using the 5-day Ifosfamide-Carboplatin-Etoposide regimen. The main objective was to determine the complete response rate. Forty-five patients were included between September 2004 and December 2007: 44 received the first HDCT cycle, 39 two HDCT cycles, 29 could receive the whole protocol. Sixteen patients did not receive the entire protocol, including eight (17.7%) for toxic side-effects. Two patients (4.4%) died of toxicities, and 17 (37.7%) of disease progression. With a median follow-up time of 26 months (range, 4-51), the final overall response rate was 48.8% (including a complete response rate of 15.5% and a partial response/negative serum markers rate of 26.6%) in an intent-to-treat analysis. The median progression-free survival (PFS) and overall survival (OS) times were 22 months [95% confidence interval (CI) 2-not reached] and 32 months (95% CI 4-49), respectively. The 2-year PFS was a plateau setup at 50% (95% CI 32-67) and the 2-year OS was 66% (95% CI 44-81). The TAXIF II protocol was effective in nonrefractory GCT patients failing Cisplatin-based chemotherapy. The toxic death rate remained acceptable in the field of HDCT regimens. NCT00231582.

18 June 2016 in Oncotarget
Verified
Journal Article
Open access
MSMarie-Paule Sablin
Marie-Paule Sablin
CDCoraline Dubot
Coraline Dubot
JKJerzy Klijanienko
Jerzy Klijanienko
SVSophie VACHER
Sophie VACHER
LOLamia Ouafi
Lamia Ouafi
CTChristophe Le Tourneau
Christophe Le Tourneau
Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas